Off-Label Fraud Case Against Pfizer Headed to Appeals Court

Three issues that could determine the viability of the majority of a False Claims Act lawsuit against drugmaker Pfizer merit an immediate appeal (United States ex rel. Brown v. Pfizer, Inc., 2017 BL 214676, E.D. Pa., No. 05-cv-6795, 6/22/17).

The U.S. District Court for the Eastern District of Pennsylvania June 22 certified three questions of law to be heard by the U.S. Court of Appeals for the Third Circuit in a whistle-blower lawsuit and halted the rest of the litigation against Pfizer. The court denied Pfizer’s motion to dismiss the lawsuit in an April 12 ruling, finding that ...